JG
AMLX icon

Jain Global’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jain Global’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517K Buy
+28,770
New +$445K ﹤0.01% 1195
2025
Q2 		– Sell
-73,942
Closed -$262K – 1167
2025
Q1 		$262K Buy
+73,942
New +$263K ﹤0.01% 727

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jain Global's AMLX Position: Q2 2026 in Review

Jain Global opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 28,770 shares worth $517K. The stake represents ﹤0.01% of the portfolio and ranks #1195 among its holdings. This is a return to the name: Jain Global previously reported a position in AMLX as recently as Q1 2025.

Jain Global first reported a position in AMLX in Q1 2025 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Jain Global held 28,770 shares of Amylyx Pharmaceuticals worth $517K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Jain Global position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Jain Global's portfolio in Q2 2026, its #1195 holding.
  • Jain Global first reported a position in Amylyx Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.